Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-07
2011-11-15
Sullivan, Daniel (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C562S439000, C560S034000
Reexamination Certificate
active
08058449
ABSTRACT:
Compounds of Formula (Ia)wherein R is a C6-C12substituted or unsubstituted aryl, a C6-C12substituted or unsubstituted heteroaryl, a C1-C6substituted or unsubstituted alkyl or —NR′R′,Q is C(O), O, NR′, S, S(O)2, C(O)2(CH2)pY is C(O), O, NR′, S, S(O)2, C(O)2(CH2)pZ is H or C1-C4alkyl,R′ is H, C(O), S(O)2, C(O)2, a C6-C12substituted or unsubstituted aryl, a C6-C12substituted or unsubstituted heteroaryl or a C1-C6substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.
REFERENCES:
patent: 3527789 (1970-09-01), Payne
patent: 4885136 (1989-12-01), Katayama et al.
patent: 4888136 (1989-12-01), Chellapa et al.
patent: 5442088 (1995-08-01), Hoffmann
patent: 5672592 (1997-09-01), Jackson et al.
patent: 5739123 (1998-04-01), Norcini et al.
patent: 5795877 (1998-08-01), Jackson et al.
patent: 5824662 (1998-10-01), Slusher et al.
patent: 5880112 (1999-03-01), Jackson et al.
patent: 6071965 (2000-06-01), Jackson et al.
patent: 6479470 (2002-11-01), Kozikowski et al.
patent: 6528499 (2003-03-01), Kozikowski et al.
patent: 7381745 (2008-06-01), Kozikowski et al.
patent: 2004/0002478 (2004-01-01), Kozikowski et al.
patent: 2004/0054190 (2004-03-01), Pomper et al.
patent: 2006/0155021 (2006-07-01), Lenges et al.
patent: 2006/0155146 (2006-07-01), Lenges et al.
patent: 2006/0198785 (2006-09-01), Santos et al.
patent: 2008/0176821 (2008-07-01), Kozikowski et al.
patent: 2011/0008253 (2011-01-01), Babich et al.
patent: 0878463 (1998-11-01), None
patent: WO 97/48399 (1997-12-01), None
patent: WO 97/48400 (1997-12-01), None
patent: WO 97/48409 (1997-12-01), None
patent: WO 98/13046 (1998-04-01), None
patent: WO 98/45256 (1998-10-01), None
patent: WO 98/45257 (1998-10-01), None
patent: WO 99/33847 (1999-07-01), None
patent: WO 00/64911 (2000-11-01), None
patent: WO 01/01974 (2001-01-01), None
patent: WO 02/22627 (2002-03-01), None
patent: WO 03/060523 (2003-07-01), None
patent: WO 2006093991 (2006-09-01), None
patent: WO 2008058192 (2008-05-01), None
Office Action in U.S. Appl. No. 12/029,367 mailed Oct. 19, 2010.
Carter, R., et al., “Prostate-Specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase,” Proc. Nan Acad. Sci. USA, 93:749-753 (Jan. 23, 1996).
Gasparini, F., et al., “(R.S)-4-phosphononphenyglince, a Potent and Selective Group III Metabotropic Glutamate Receptor Agonist, Is Anticonvulsive and Neuroprotective In Vivo,” J. of Pharm. & Exper. Thera ., 289(3):1678-1687, (Jun. 1, 1999).
Izdebski, J. and Pawlak, D., “Synthesis of N,N′—Carbonyl-bis amino Acids and N,N′—Carbonyl-bis-peptides,” Polish J. Chem., 71(8):1066-1074, (1997).
Jackson, P., et al., “Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase NAcetylated or Linked Acidic Dipeptidase,” J. Med. Chem, 39(2):619-622 (Jan. 19, 1996).
Kozikowski, A., et al., “Design of Remarkably Simple, Yet Potent Urea-Based Inhibitors of Glutamate Carboxypeptidase II (NAALADase),” J. Med. Chem. 44(3):298-301 (Feb. 1, 2001).
Lewis, R. J., Sr., Hawley's Condensed Chemical Dictionary, 12 Ed., Van Nostrand Reinhold Co., New York, NY, 9, 420, 421 and 881, (1993).
Nam F., et al., “Dual Function Glutamate-Related Ligands: Discovery of a Novel. Potent Inhibitor of Glutamate Carboxypeptidase II Possissing mGluR3 Agonist Activity,” J. Med. Chem., 43(5):772-774 (Mar. 9, 2000).
Slusher, B., et al., “Rat Brain N-Acetylated or Linked Acidic Dipeptidase Activit,” The Journal of Biological Chemistry, 265(34):21297-321301 (1990).
Slusher, B., et al., “Immunocytochemical Localization of the N-Acety-Aspartyl-Glutamate (NAAG) Hydrolyzing Enzyme N-Acetylated or Linked Acidic Dipeptidase (NAALADase),” The Journal of Comparative Neurology, 315(2):217-229 (Jan. 8, 1992).
6001 Chemical Abstracts, Columbus, Ohio, US, 101(27). XP 002196919 (Oct. 22, 1984).
International Search Report for International Application No. PCT/US2000/011262 mailed Sep. 12, 2000.
International Search Report for International Application No. PCT/US2007/083934 mailed Mar. 13, 2008.
Babich John W.
Maresca Kevin P.
Zimmerman Craig N.
Greenberg & Traurig, LLP
Molecular Insight Pharmaceuticals, Inc.
Pham Chinh H.
Sullivan Daniel
Valenrod Yevegeny
LandOfFree
Heterodimers of glutamic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterodimers of glutamic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterodimers of glutamic acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4288811